Astrazeneca

Oncology
Oncology 2022

Deep Dive: Oncology 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.

News
Imfinzi1

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory.